The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease

Contraception

Volumn 54, Issue 3, 1996, Pages 163-168

  Spinillo, Arsenio ^a,b   Gorini, Giovanna ^a   Piazzi, Gaia ^a   Baltaro, Federica ^a   Monaco, Antonio ^a   Zara, Francesca ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chlamydia trachomatis; oral contraceptives; pelvic inflammatory disease

Indexed keywords

IMMUNOGLOBULIN A; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHLAMYDIASIS; FEMALE; HORMONAL CONTRACEPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INFECTION RISK; MAJOR CLINICAL STUDY; PELVIC INFLAMMATORY DISEASE; PREVALENCE; RISK ASSESSMENT; SEXUALITY;

EID: 0030250737     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(96)00172-2     Document Type: Article

References (15)

1. 1. Senayake P, Kramer DG. Contraception and the etiology of pelvic inflammatory disease: New perspectives. Am J Obstet Gynecol 1980;138:852-60.
2. 2. Washington AE, Gove S, Schachter J, Sweet RL. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease. A word of caution about protection. JAMA 1985;253:2246-50.
3. 3. Cotthingham J, Hunter D. Chlamydia trachomatis and oral contraceptive use: a quantitative review. Genitourin Med 1992;68:209-16.
4. 4. Wonler-Hanssen P, Eschembach DA, Paavonen J, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990;263:54-9.
5. 5. Soper DE. Diagnosis and laparoscopic grading of acute salpingitis. Am J Obstet Gynecol 1991;164:1370-6.
6. 6. Ripa KT, Mardh PA. Cultivation of Chlamydia trachomatis in cycloheximide-treated McCoy cells. J Clin Microbiol 1977;6:328-31.
7. 7. Amsel R, Totten PA, Spiegel CA, Chen KCS, Escenbach D, Holmes KK. Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiological associations. Am J Med 1983;74:14-22.
8. 8. Rothman KJ. Modern epidemiology. Boston: Little, Brown and Co., 1986.
9. 9. Cevenini R, Sarov I, Rumpianesi F, et al. Serum specific IgA antibody to Chlamydia trachomatis in patients with chlamydial infections detected by ELISA and an immunofluorescence test. J Clin Pathol 1984;37:686-91.
10. 10. Gates W, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771-81.
11. 11. The Italian MEGIC group. Determinants of cervical Chlamydia trachomatis infection in Italy. Genitourin Med 1993;69:123-5.
12. 12. Rolfs RT, Galaid EI, Zaidi AA. Pelvic inflammatory disease: trends in hospitalizations and office visits, 1979 through 1988. Am J Obstet Gynecol 1992;166:983-90.
13. 13. Maslow AS, Davis CH, Choong J, Wyrick PB. Estrogen enhances attachment of Chlamydia trachomatis to human endometrial epithelial cells in vitro. Am J Obstet Gynecol 1988;159:1006-14.
14. 14. Washington AE, Aral SO, Wolner-Hanssen P, Grimes DA, Holmes KK. Assessing risk for pelvic inflammatory disease and its sequelae. JAMA 1991;266:2581-6.
15. 15. Mehanna MTR, Rizk MA, Schachter J. Chlamydial serologic characteristics among intrauterine contraceptive device users: does copper inhibit chlamydial infection in the female genital tract? Am J Obstet Gynecol 1994;171:691-3.